Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 7,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions: ATTO-3712, Placebo; Drug
Lead sponsor: Attovia Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Encinitas, California • Fountain Valley, California • Huntington Beach, California + 6 more

Conditions: Opioid Use Disorder
Interventions: intranasal oxytocin, 40 IU, twice a day for 7 days; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Asthma in Children, Atopy, Viral Upper Respiratory Infection
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 6 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Gastric Cancer
Interventions: 5-Fluorouracil, Ipatasertib, Leucovorin, Oxaliplatin, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Houston, Texas

Conditions: Non-small Cell Lung Cancer (NSCLC), Cachexia
Interventions: ponsegromab, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Decatur, Illinois • O'Fallon, Illinois • Garland, Texas + 1 more

Conditions: Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Hidradenitis Suppurativa
Interventions: PTM-001, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Redwood City, California • Worcester, Massachusetts • Cincinnati, Ohio

Conditions: Community-acquired Bacterial Pneumonia
Interventions: Solithromycin, Moxifloxacin, Placebo to match solithromycin; Drug · Other
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 25
States / cities: Glendale, California • Los Angeles, California • Mission Hills, California + 18 more

Conditions: Crohn's Disease
Interventions: Serum-derived Bovine Immunoglobulin / Protein Isolate, Placebo; Other
Lead sponsor: Entera Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: North Little Rock, Arkansas • Hollywood, Florida • Winter Park, Florida + 3 more

Conditions: HIV Infections
Interventions: Minocycline, Placebo (Tetracycline); Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years to 65 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • Denver, Colorado + 13 more

Conditions: Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: LCQ908, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Mobile, Alabama • San Diego, California • Gainesville, Florida + 8 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • Santa Barbara, California • Torrance, California + 7 more

Conditions: Chronic Migraine
Interventions: Atogepant 30 mg, Atogepant 60 mg, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 41
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 35 more

Conditions: Major Depressive Disorder, Depression
Interventions: TC-5214 + citalopram, Placebo + citalopram; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Miami, Florida • Cincinnati, Ohio • Dallas, Texas

Conditions: Psoriasis
Interventions: Placebo, SRT2104; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: St Louis, Missouri • New York, New York • Portland, Oregon + 4 more

Conditions: Crohn's Disease
Interventions: SAR441566, SAR441566 matching Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 19
States / cities: Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more

Conditions: Depression, Postpartum
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 68
States / cities: Scottsdale, Arizona • Bentonville, Arkansas • Anaheim, California + 62 more

Conditions: Major Depressive Disorder (MDD)
Interventions: SPN-821 2400 mg, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more

Conditions: Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility
Interventions: Ramipril, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: MN-221, Placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: Loma Linda, California • San Diego, California • Sylmar, California + 11 more

Conditions: Healthy Volunteers
Interventions: AZD8108, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Adult Attention-Deficit Hyperactivity Disorder
Interventions: Guanfacine Hydrochloride, Placebo; Drug · Other
Lead sponsor: Rochester Center for Behavioral Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester Hills, Michigan

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Garadacimab, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 40 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 19 more

Conditions: Ileus
Interventions: MOA-728, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 75
States / cities: Benton, Arkansas • Colton, California • Laguna Hills, California + 62 more

Search by objective public record fields.

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

Oxytocin, Stress, Craving, Opioid Use Disorder

Omalizumab Before Onset of Exacerbations

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease

Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults

Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

TC-5214 as add-on the Treatment of Major Depressive Disorder

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

Ramipril for the Treatment of Oligospermia

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

AZD8108 SAD/MAD in Healthy Volunteers

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).

Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair